Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...

Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...

The story of modern medicine is full of accidental heroes. Penicillin came from a petri dish left open too long. Viagra began as a blood-pressure drug that wandered off in an unexpected direction. And ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...